AZN Stock Recent News

AstraZeneca PLC (LSE:AZN) has once again shown why it sits at the top table of global pharmaceuticals. Although first-quarter sales missed City forecasts by a whisker, profits came in well ahead of expectations, keeping the company firmly on track for a year of solid growth.

The chief executive of AstraZeneca said on Tuesday that the drugmaker will maintain its 2025 sales guidance even if the U.S. levies tariffs on pharma products made in the European Union, provided they are in line with rates for other sectors.

The drugmaker posted increased core earnings per share and sales for the first quarter, but also said it could face a fine of up to $8 million in China.

Shares in AstraZeneca PLC (LSE:AZN) fell 4% in early trading after first-quarter revenues missed City forecasts, as investors looked past stronger-than-expected earnings and a standout performance from its oncology portfolio. The Anglo-Swedish drugmaker reiterated its guidance for the full year, forecasting high single-digit percentage growth in total revenue and a low double-digit percentage rise in core earnings per share at constant exchange rates.

AstraZeneca on Tuesday said it had received an opinion from authorities in Shenzhen city of suspected unpaid import taxes of $1.6 million, adding that a fine of one to five times that amount may be levied if the company is found liable.

BOSTON and ROLLE, Switzerland , April 28, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and global leader in data-driven medicine, today announced the expansion of its ongoing collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) to accelerate the deployment of MSK-ACCESS® powered with SOPHiA DDM™ globally. Building on the initial collaboration announced in October 2024 , this new phase will extend the test's reach to a total of 30 clinical institutions worldwide in 2025.

VANCOUVER, BC / ACCESS Newswire / April 24, 2025 / Onco-Innovations Limited (CSE:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H,WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that its wholly owned subsidiary, Inka Health Corp. ("Inka Health"), signed a new analytical work contract[1] with AstraZeneca Canada ("AstraZeneca") on March 20, 2025 to support the next phase of real-world evidence (RWE) research and scientific dissemination. The Company perceives this renewed engagement as a meaningful signal of confidence in Inka Health's capacity to support drug evaluation, submission strategies, and evidence planning within Canada's regulatory framework.

Tempus AI TEM has skyrocketed 21% in the last three days, fueled by news of a $200 million partnership with AstraZeneca AZN and Pathos AI. The multi-year deal focuses on building a multimodal AI-driven foundation model for oncology, using TempusAI's de-identified oncology data.

Get a deeper insight into the potential performance of Astrazeneca (AZN) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Tempus AI (NASDAQ:TEM) said on Wednesday it has signed multi-year strategic collaborations with AstraZeneca (AZN.L) and Pathos AI to co-develop what it called the largest multimodal foundation model in oncology, sending its shares up more than 15% in morning trading. The deals, which include $200 million in data licensing and model development fees to Tempus, will leverage the company's vast repository of de-identified oncology data and artificial intelligence capabilities to help identify new drug targets and advance cancer therapies.